Curanex Pharmaceuticals Inc
Research Curanex Pharmaceuticals Inc (CURX) on Bullrun: market cap USD 7.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCURX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 7.53M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.29M
- Free cash flow-USD 1.08M
Valuation Snapshot
latest market cap is USD 7.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 4.23M | -USD 10.48M | n/a | -0.17 | USD 5.00M | USD 346.70K | USD 11.22M |
| FY2024 | USD 0 | -USD 361.51K | -USD 555.58K | n/a | -0.03 | USD 148.89K | USD 0 | USD 503.36K |
| FY2023 | USD 0 | -USD 19.20K | -USD 120 | n/a | -0.01 | USD 74.37K | n/a | USD 60.09K |
| FY2022 | USD 26.00K | -USD 20.23K | USD 3.34K | 17.0% | -0.4 | USD 2.43K | n/a | USD 10.23K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 7.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 9.35M | n/a | n/a | n/a |
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Curanex Pharmaceuticals Inc's market cap?
Curanex Pharmaceuticals Inc's market capitalization is USD 7.53M.
What does Curanex Pharmaceuticals Inc do?
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.